MYGN vs NTLA: stock comparison and AI forecast
Myriad Genetics Inc (MYGN) and Intellia Therapeutics, Inc. (NTLA) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
MYGN Myriad Genetics Inc
- Price
- $5.92 +44.7% · 6M
- Market Cap
- $566M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
NTLA Intellia Therapeutics, Inc.
- Market Cap
- $1.59B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- NTLA is 2.8 times larger than MYGN by market capitalization ($1.59B against $566M).
- MYGN carries 1.26 times debt per unit of equity, against 0.47 times for NTLA.
- Both companies share the SEC industry classification In Vitro & In Vivo Diagnostic Substances.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | MYGN | NTLA |
|---|---|---|
| Market Cap | $566M | $1.59B |
| P/B Ratio | 2.11x | 2.59x |
| EPS | $-4.58 | $-2.52 |
| Book Value/Share | $2.81 | $4.38 |
| Revenue/Share | $8.40 | $0.38 |
| FCF/Share | – | $-2.56 |
Profitability & Margins
| Metric | MYGN | NTLA |
|---|---|---|
| ROE | – | -69.5% |
| ROA | – | -47.2% |
| ROIC | -24.4% | -52.8% |
| Gross Margin | 68.3% | – |
| Operating Margin | -14.3% | -821.2% |
| Net Margin | – | -805.8% |
| EBT Margin | -16.1% | -821.2% |
| Tax Rate | 0.1% | – |
Financial Health
| Metric | MYGN | NTLA |
|---|---|---|
| Current Ratio | 1.98x | 6.31x |
| Quick Ratio | 1.77x | – |
| D/E Ratio | 1.26x | 0.47x |
| Financial Leverage | 2.26x | 1.47x |
| Interest Coverage | -11.7x | -200.2x |
| Working Capital | $134M | $426M |
Cash Flow
| Metric | MYGN | NTLA |
|---|---|---|
| Operating Cash Flow | -$14M | -$355M |
| Free Cash Flow | – | -$358M |
| Capital Spending | – | -$3M |
| FCF/Sales | – | -677.1% |
| CapEx/Sales | – | 5.5% |
Operational Efficiency
| Metric | MYGN | NTLA |
|---|---|---|
| Asset Turnover | 1.32x | 0.06x |
| Receivables Turnover | 7.6x | 7.0x |
| Inventory Turnover | 8.9x | – |
| Fixed Assets Turnover | 7.7x | 3.8x |
| Days Sales Outstanding | 48 days | 52 days |
| Days Inventory | 41 days | – |
| Payables Period | 40 days | – |
| Cash Conversion Cycle | 49 days | – |
Income Statement
| Metric | MYGN | NTLA |
|---|---|---|
| Total Revenue | $804M | $53M |
| Operating Income | -$115M | -$434M |
| Net Income | – | -$426M |
| R&D Expense | $104M | $335M |
| SG&A Expense | $604M | – |
| Cost of Goods Sold | $254M | – |
Dividend & Shareholder Information
| Metric | MYGN | NTLA |
|---|---|---|
| Shares Outstanding | 96M | 140M |
MYGN vs NTLA: stock comparison and AI forecast
Which is bigger, MYGN or NTLA?
NTLA is 2.8 times larger than MYGN by market capitalization ($1.59B against $566M).
Which one does Intratio's AI model rank higher, MYGN or NTLA?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.